vs
Guardant Health, Inc.（GH）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是Guardant Health, Inc.的1.6倍（$461.6M vs $281.3M），RBC Bearings INC净利率更高（14.6% vs -45.7%，领先60.3%），Guardant Health, Inc.同比增速更快（39.4% vs 17.0%），RBC Bearings INC自由现金流更多（$99.1M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 5.6%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
GH vs RBC — 直观对比
营收规模更大
RBC
是对方的1.6倍
$281.3M
营收增速更快
GH
高出22.3%
17.0%
净利率更高
RBC
高出60.3%
-45.7%
自由现金流更多
RBC
多$153.3M
$-54.2M
两年增速更快
GH
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $461.6M |
| 净利润 | $-128.5M | $67.4M |
| 毛利率 | 64.6% | 44.3% |
| 营业利润率 | -43.0% | 22.3% |
| 净利率 | -45.7% | 14.6% |
| 营收同比 | 39.4% | 17.0% |
| 净利润同比 | -15.8% | 16.4% |
| 每股收益（稀释后） | $-1.01 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRBC
| Q4 25 | $281.3M | $461.6M | ||
| Q3 25 | $265.2M | $455.3M | ||
| Q2 25 | $232.1M | $436.0M | ||
| Q1 25 | $203.5M | $437.7M | ||
| Q4 24 | $201.8M | $394.4M | ||
| Q3 24 | $191.5M | $397.9M | ||
| Q2 24 | $177.2M | $406.3M | ||
| Q1 24 | $168.5M | $413.7M |
净利润GHRBC
| Q4 25 | $-128.5M | $67.4M | ||
| Q3 25 | $-92.7M | $60.0M | ||
| Q2 25 | $-99.9M | $68.5M | ||
| Q1 25 | $-95.2M | $72.7M | ||
| Q4 24 | $-111.0M | $57.9M | ||
| Q3 24 | $-107.8M | $54.2M | ||
| Q2 24 | $-102.6M | $61.4M | ||
| Q1 24 | $-115.0M | — |
毛利率GHRBC
| Q4 25 | 64.6% | 44.3% | ||
| Q3 25 | 64.7% | 44.1% | ||
| Q2 25 | 65.0% | 44.8% | ||
| Q1 25 | 63.3% | 44.2% | ||
| Q4 24 | 61.6% | 44.3% | ||
| Q3 24 | 61.1% | 43.7% | ||
| Q2 24 | 59.1% | 45.3% | ||
| Q1 24 | 61.2% | 43.1% |
营业利润率GHRBC
| Q4 25 | -43.0% | 22.3% | ||
| Q3 25 | -37.3% | 21.5% | ||
| Q2 25 | -45.9% | 23.2% | ||
| Q1 25 | -54.6% | 23.0% | ||
| Q4 24 | -62.4% | 21.7% | ||
| Q3 24 | -61.3% | 21.6% | ||
| Q2 24 | -56.8% | 24.0% | ||
| Q1 24 | -59.2% | 22.8% |
净利率GHRBC
| Q4 25 | -45.7% | 14.6% | ||
| Q3 25 | -35.0% | 13.2% | ||
| Q2 25 | -43.0% | 15.7% | ||
| Q1 25 | -46.8% | 16.6% | ||
| Q4 24 | -55.0% | 14.7% | ||
| Q3 24 | -56.3% | 13.6% | ||
| Q2 24 | -57.9% | 15.1% | ||
| Q1 24 | -68.2% | — |
每股收益（稀释后）GHRBC
| Q4 25 | $-1.01 | $2.13 | ||
| Q3 25 | $-0.74 | $1.90 | ||
| Q2 25 | $-0.80 | $2.17 | ||
| Q1 25 | $-0.77 | $2.33 | ||
| Q4 24 | $-0.90 | $1.82 | ||
| Q3 24 | $-0.88 | $1.65 | ||
| Q2 24 | $-0.84 | $1.90 | ||
| Q1 24 | $-0.94 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $107.6M |
| 总债务越低越好 | $1.5B | $990.2M |
| 股东权益账面价值 | $-99.3M | $3.3B |
| 总资产 | $2.0B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资GHRBC
| Q4 25 | $378.2M | $107.6M | ||
| Q3 25 | $580.0M | $91.2M | ||
| Q2 25 | $629.1M | $132.9M | ||
| Q1 25 | $698.6M | $36.8M | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | $76.8M | ||
| Q1 24 | $1.0B | $63.5M |
总债务GHRBC
| Q4 25 | $1.5B | $990.2M | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $915.6M | ||
| Q1 25 | $1.1B | $920.1M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益GHRBC
| Q4 25 | $-99.3M | $3.3B | ||
| Q3 25 | $-354.5M | $3.2B | ||
| Q2 25 | $-305.5M | $3.1B | ||
| Q1 25 | $-250.8M | $3.0B | ||
| Q4 24 | $-139.6M | $2.9B | ||
| Q3 24 | $-60.1M | $2.9B | ||
| Q2 24 | $-1.6M | $2.8B | ||
| Q1 24 | $68.3M | $2.8B |
总资产GHRBC
| Q4 25 | $2.0B | $5.1B | ||
| Q3 25 | $1.3B | $5.1B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.5B | $4.7B | ||
| Q3 24 | $1.5B | $4.7B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.7B | $4.7B |
负债/权益比GHRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $99.1M |
| 自由现金流率自由现金流/营收 | -19.3% | 21.5% |
| 资本支出强度资本支出/营收 | 9.9% | 5.0% |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRBC
| Q4 25 | $-26.4M | $122.1M | ||
| Q3 25 | $-35.4M | $88.4M | ||
| Q2 25 | $-60.3M | $120.0M | ||
| Q1 25 | $-62.7M | — | ||
| Q4 24 | $-64.5M | $84.0M | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-94.0M | $97.4M | ||
| Q1 24 | $-30.3M | — |
自由现金流GHRBC
| Q4 25 | $-54.2M | $99.1M | ||
| Q3 25 | $-45.8M | $71.7M | ||
| Q2 25 | $-65.9M | $104.3M | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | $73.6M | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | $88.4M | ||
| Q1 24 | $-37.2M | — |
自由现金流率GHRBC
| Q4 25 | -19.3% | 21.5% | ||
| Q3 25 | -17.3% | 15.7% | ||
| Q2 25 | -28.4% | 23.9% | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | 18.7% | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | 21.8% | ||
| Q1 24 | -22.1% | — |
资本支出强度GHRBC
| Q4 25 | 9.9% | 5.0% | ||
| Q3 25 | 3.9% | 3.7% | ||
| Q2 25 | 2.4% | 3.6% | ||
| Q1 25 | 2.2% | 3.2% | ||
| Q4 24 | 9.4% | 2.6% | ||
| Q3 24 | 2.2% | 4.1% | ||
| Q2 24 | 2.9% | 2.2% | ||
| Q1 24 | 4.1% | — |
现金转化率GHRBC
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 1.75× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
